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PREFACE
This report describes the study results achieved over two periods of related
activity, June-December 1977 and March-October 1978. It is organized in three
volumes to meet the needs of different audiences. The first, an executive summary,
serves as an overview aimed at those responsible for committing public and private
resources to new ventures. The second recounts the activities of the study and
presents fundamental lessons learned. This volume is intended to serve two
groups: those in the aerospace industry who may wish to have a model for their
efforts to attract participation in space processing by other industries; and
those in nonaerospace industries who want to learn more about the possibilities of
space processing. The third volume contains the detailed product data collected
and reviewed to support the activities in Volume II.
The report has been organized to take the reader through the chronology of
the study process. Although many of these steps were accomplished simultaneously,
we have -- for simplicity and clarity -- organized them into discrete segments,
moving first through the plan established to target and contact pharmaceutical
companies, then the laboratory work needed to support the expanding company-to-
company cooperation and technology interchange, through the literature search and
analysis of potential products and finally through the production engineering
analysis. The report then summarizes the study by identifying the lessons learned
during the course of its execution. Before the enormous potential benefits of
space processing can reach the public -- the basic goal of NASA's Materials
Processing in Space program -- industry must be willing to participate in the
development of processes. Such investment, however, will not follow until industry
itself is made aware of the promise of space processing and is supplied with hard
data supporting such promises. It is to this purpose that we have directed our
efforts.
This report is submitted under NASA Contract Number NAS8-31353. The work was
performed by McDonnell Douglas Astronautics Company - St. Louis Division under the
direction of William R. Marx and Dr. Ronald A. Weiss, Study Managers during the
first and second periods of the study respectively. This contract was administered
by the NASA Marshall Space Flight Center, Huntsville, Alabama.
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This report was prepared under the direction of Dr. Ronald A. Weiss, with the
assistance of the principal contributors listed below:
J. Wayne Lanham, Ph.D. David W. Richman
Steven J. Blaisdell Norbert W. Burlis
Requests for further information regarding the results of this study should
be directed to:
Kenneth R. Taylor Ronald A. Weiss, Ph.D.
NASA Marshall Space Flight Center McDonnell Douglas Astronautics Company
Code PS06 P.O. Box 516
Huntsville, AL 35812 St. Louis, MO 63166
Telephone:. (205) 453-3424 Telephone: (314) 232-2008
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FOREWORD
As the principal result of this study activity, the McDonnell Douglas
Astronautics Company - St. Louis Division, elicited and fostered the participation
of several pharmaceutical firms, to varying degrees, in exploring the potential
benefits which may accrue from processing Pharmaceuticals in space.
One of the conditions for their participation, however, was that the companies
not be linked with any potential product or process because of the highly competi-
tive nature of the industry. With NASA concurrence, therefore, and participating
company approval, we have deleted the names of any company associated with this
study in order to be able to emphasize the important product data and technology
interchange achieved with them.
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1.0 INTRODUCTION
The environment of space holds great promise for new manufacturing processes which
take advantage of the absence of such earthbound phenomena as natural convection
and sedimentation. Using these processes, space manufacturers can not only produce
products superior to those produced on the ground, they can produce entirely new
classes of products. Though characteristics of space -- including high vacuum and
radiation -- can be duplicated on earth, the most important characteristic, weight-
lessness, can be achieved only for an extremely brief period. In the microgravity
of space, molten materials can be suspended without containers — eliminating a
major source of contaminants. More importantly, in space we can escape gravity-
induced convection. Convection currents — which are caused by the thermal
gradients in fluids -- can lead to undesirable structural differences in the solid
materials produced. Having escaped the problems posed by these currents, space
manufacturers will be able to grow crystals of great purity with highly control-
lable characteristics; they will find it much easier to mix and homogenize liquids,
to cast metals, and to separate and purify the elements of mixtures.
The question immediately arises, why is not industry actively pursuing opportuni-
ties to develop materials and processes in space? The first reason is that
industry is not generally familiar with the potentials of space. NASA and key
aerospace organizations are working continually to rectify that situation. The
second, and by far the dominant, reason is that observation of basic phenomena
with potential application is only the start of the industrial process. A major
body of data on applied research into processes and materials characteristics,
material applications potential, potential markets and their probable growth, and
the characteristics of production systems and logistics must be developed as a
vital decision base. Before private industry will invest the money required to
begin such untried processes, it must be reasonably confident that the product
will have a high value, that the benefits of processing in space will be substan-
tially greater than processing on the ground (i.e., capable of producing less
expensive, more useful products, or producing products that cannot be made on
earth). The investor must also be reasonably confident: that the space process
can be developed in a given time at an affordable cost; that a market exists at a
price which assures a reasonable return on investment; and that this market will
1
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not disappear because a new product appears and captures the market, or because a
breakthrough in the technology occurs that permits competitive ground production.
Because these risks are so difficult to assess, and because the required initial
investment is so large, most industries adopt a "wait and see" attitude. Until
more data are available, industries find it extremely difficult to assess the
potential of new processes and products.
To address this problem, we approached NASA with a proposal to study the feasibil-
ity of commercial manufacturing of Pharmaceuticals. The goal of this undertaking
was to induce pharmaceutical firms to participate actively, on a continuing basis,
in exploring the possibilities of using the unique environment of space to produce
new products. The MDAC-St. Louis' approach was, first, to secure the initial
commitment of these firms by providing key management and technical executives
with preliminary data and forecasts of the business and technical potential of
space processing. The second aspect of the approach was to foster the initial
commitments by establishing continuing technical and management exchanges with the
interested pharmaceutical companies to our mutual benefit.
Our enthusiasm for space processing focused on the promise shown by our company
funded efforts with electrophoresis. In order to accomplish the facets of this
goal, we had to expand the data base we had developed -- including significant
laboratory work and an awareness of the state-of-the-art — and we had to target
companies potentially interested in the benefits of the process.
In our early company funded work with electrophoresis, we learned how to separate
relatively large quantities of test materials. We also experienced the adverse
effects of gravity on the process -- causing the vertically flowing stream to
collapse on itself (if the sample were denser than the carrier fluid) or to ball
up and float to the top of the chamber (if the sample is less dense than the
carrier fluid). On the basis of these experiences we began developing, with
MDAC-St. Louis funds, our own mathematical models of these effects so that we
could predict effects of design changes and operating conditions, and ultimately
forecast the benefits of operating in space. We also ran company funded prelimi-
nary mass balance calculations; these activities assured us that we could define
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and demonstrate the types of requirements needed to characterize conceptual space
and ground production systems, with their requisite logistics capabilities, in
presentations to NASA -and industry.
Under the contract, we addressed the problem of targeting pharmaceutical companies.
Our first step was to engage the services of Price Waterhouse and Company to
provide important drug industry data. The overall drug industry analysis provided
by Price Waterhouse included: detailed assessments of the top twenty companies in
the industry, focusing on their apparent commitment to innovation, their research
and production emphasis on products having high potential for space production,
and the prominence of their executives. Price Waterhouse also helped us prepare
the presentation to be made to these companies, recommending a "businessman to
businessman" approach. ,
Letters were written to the selected companies. These letters gave an overview of
the feasibility study, listed some of the potential benefits to pharmaceutical
manufacturing by processing in space, and requested an opportunity to make a
presentation. Ten pf fourteen companies requested the presentation.
Although the pharmaceutical company personnel were generally skeptical at first,
once they understood the benefits of micrbgravity;, the implications of the prelimi-
nary /results of: continuous? flow el ectrophoretic separation, and the potential of an
integrated space pharmaceutical production system manufacturing products of great
value, they became increasingly intrigued. As a result of these initial contacts,
six companies responded positively to our invitation for assistance and coopera-
tion in this study. Two companies agreed to participate actively in the form of
laboratory testing a product of specific interest to themselves. Four additional
fj": rig iiwrKetiriy information and reviewing the analysis of results. One of the
conditions for their participation, however, was that the companies not be linked
with any potential product or process data because of the highly competitive
nature of the industry. With NASA concurrence, therefore, and participating
company approval, we have deleted the names of any company associated with this
study and, instead, emphasized the important product and process information
obtained from them.
. I.OCM OfVWOM
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This report describes our method of obtaining pharmaceutical company involvement,
the development of protocols with two of these companies, laboratory results of
the separation of serum proteins by the continuous flow electrophoresis process,
the selection and study of candidate products, and their production requirements.
From the twelve candidate products discussed with, or suggested by, the visited
pharmaceutical companies, six were selected for further evaluation; antihemophilic
factor, beta cells, erythropoietin, epidermal growth factor, alpha-1-antitrypsin
and interferon. Production mass balances for antihemophilic factor, beta cells,
and erythropoietin were compared for space versus ground operation. Selection of
the best mode of operation for these three representative products permitted a
conceptual description of a multiproduct processing system for space operation.
Production requirements for epidermal growth factor, alpha-1-antitrypsin and
interferon were found to be satisfied by the system concept.
In the technical interchanges that occurred with these pharmaceutical companies,
significant data were generated and many valuable lessons were learned. These
data and lessons, detailed in this report, are intended to serve others interested
in exploring the possibilities of space processing.
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2.0 PHARMACEUTICAL COMPANY INVOLVEMENT
The aspiration of this task -was to obtain the participation of one or more promi-
nent ethical drug manufacturers in this study and gain their evaluation of product
and process commercial feasibility. The industrialization of space, and any
resultant social benefits, would not be realized at any early date without the
cooperation, endorsement, and initiative of commercial industry. Our approach
consisted of an analysis of the drug industry and identification of primary candi-
date companies for potential study participation. Communications were then estab-
lished with a number of these companies for the purpose of gaining the assistance
of one or more of them in product selection and evaluation.
Selection of potential,pharmaceutical company participants was limited to domestic
United States ethical drug producers. The task was principally accomplished
through subcontract with the St. Louis office of the business consultant firm of
Price Waterhouse and Company. This firm has considerable knowledge of the pharma-
ceutical industry, its key personnel and the environment in which they operate.
Their report also included a brief overview of the ethical drug industry and
detailed information on. the pharmaceutical companies recommended as candidates for
presentations. This information included line of business data, results of opera-
tions and financial position, specific information concerning ethical drugs cur-
rently produced, biographical data on key individuals within the company, and
preferred initial contacts at each company. Throughout their consultantship,
Price Waterhouse and Company stressed the need for MDAC-St. Louis to initiate our
contacts and communicate with pharmaceutical firms strictly on a "businessman-to-
businessman" basis. Only in this way could we succeed in establishing the rapport
which would permit us to address potential areas of mutual business interest, in a
common language and with a mutual understanding of our technical and business
goals.
Active producers of ethical drugs were identified through analysis of product line
and related business data found in company annual reports, "10-K reports," and
other publicly available sources of information. This analysis resulted in the
reduction of the initial field of 100 drug firms to 42 potential candidate compa-
nies. The 42 candidates for study participation identified during this preliminary
5
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screening process were evaluated in a final screening for the purpose of first
selecting, then ranking, the candidates for initial contact. A final list of 20
candidate companies was compiled using several different selection criteria. Among
these were quantifiable factors of comparison such as industry sales position,
profitability, research and development expenditures, various financial ratios and
growth rates. The ten largest pharmaceutical firms (in terms of 1976 consolidated
net sales) were included because: 1) prominent names associated with this effort
would provide visibility and recognition; and 2) major companies would more likely
have the resources to conduct experimentation and initial financial investment.
Subjective criteria were utilized as well to evaluate each company's leadership in
new product development and other factors including top management commitment to
innovation.
This analysis of the 20 candidate pharmaceutical companies revealed that all were
potentially acceptable as participants in the study. Once these companies had
been identified for contact in rank order of desirability, letters were prepared
and sent to each selected company contact. Approximately one week later, follow-up
telephone calls were made to each of the company officials to establish dates for
fo'rmal presentations on pharmaceutical space manufacturing. These follow-up calls
were successful in setting up meeting dates with 10 of the first 14 companies.
The other four were either already involved with NASA Space Processing or were
Uninterested in a briefing on the subject. Ten was the maximum number of trips
feasible under the study budget.
The formal presentation was organized into two principal sections. The initial
section of the briefing established the meeting's objective, described MDAC-
St. Louis' product line and involvement in space and defined the NASA space •
program and objectives. It also outlined the programmatic importance of early
involvement of drug industry participants to assure the success of commercial
space development. The second section of the presentation described technical and
business objectives of the pharmaceutical study and the process system concept;
described in detail the MDAC-St. Louis' in-house experimental work accomplished to
date on continuous flow electrophoresis for use in space Coprocessing; defined
the benefits of space improved biological separation; and identified candidate
products for space processing.
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A series of vu-graphs were developed to support the formal presentation. In
addition, brochures incorporating these vu-graphs were prepared for distribution
at the conclusion of each drug company presentation. This brochure allowed the
drug company participants to review the material at their leisure after the formal
present ion, discuss it with their colleagues and come to a conclusion about
further participation.
Typically, the officials of each pharmaceutical firm were initially skeptical of
the benefits of space processing, but they were willing to listen. Following the
description of the MDAC-St. Louis laboratory experiments of continuous flow
electrophoresis and how microgravity may enhance the separation of cells or
protein substances in such a continuous flow electrophoresis system, most of the
technically oriented officials perceived the potential capability of space process-
ing to produce higher. purity and/or unique pharmaceutical products. Discussions
concerning this subject were fruitful and generally resulted in allaying of
initial skepticism. , '
Several significant accomplishments were achieved by these meetings. Probably
the most far reaching action was making the technical people present at these
meetings aware of the effects of gravity in their current and future chemical
processing activities. Another major accomplishment was making these corporate
decision makers aware of the existence of a space program in which they could
participate for the benefit of their company. They were under the impression that
the space program was conducted primarily for astronomical research, political and
military reasons. The characteristics of space applicable to both a research and
manufacturing environment had never been elucidated for them until the formal
presentation.
During the course of this study six of the ten companies contacted agreed to par-
ticipate. Of the six, two companies agreed to participate actively in the form of
laboratory testing a product of interest to themselves. The four other companies
agreed to participate in a different mode by suggesting products, providing
marketing information and reviewing the analysis of results. Several weeks after
the formal presentation, a seventh company informed us that they had started
investigating the space processing feasibility of four products of interest to
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them. They indicated that the results of this activity and a formal corporate
decision to participate in the MDAC-St. Louis study would take time. During the
course of this study, however, no formal comment to participate was forthcoming.
Three of the companies contacted chose not to participate.
The approach taken to obtain drug company participation in the study resulted in
the establishment of communications with the drug industry and general expressions
of interest. The reasons for this success are many, but of greatest importance
was the contribution of the in-house MDAC-St. Louis continuous flow electrophoresis
laboratory test results to the basic understanding of the potential benefits of
microgravity to the pharmaceutical industry. Other reasons include: 1) an
obvious commitment of MDAC-St. Louis to the program; 2) careful selection of con-
tacts; and 3) the fact that no immediate financial commitment was required of the
drug company participants. Their initial willingness to listen to the presentation
was probably tempered by curiosity about why MDAC-St. Louis was seriously consider-
ing space processing of Pharmaceuticals. Also, ah influence could be the decreas-
ing number of new Pharmaceuticals being introduced; any process or concept which
could produce multiple new and innovative products must be investigated.
The reasons why three companies have decided against participation are generally
related to a combination of the extremely long development time frame (10-15
years), long term commitment with unanswered proprietary right retention questions,
and the competition from alternative products and processes for limited corporate
research and development resources. This latter factor was of paramount importance
in two companies' responses.
The principal conclusion to draw from the decision of.the three drug firms not to
participate in the study is that despite its promise, not enough is known about
potential space processed products to allow solid forecasts of how they would
compete with other currently promising product alternatives which can be developed
along more traditional lines.
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3.0 SUPPORTING LABORATORY DATA
Prior to entering into this study for NASA, considerable work was conducted with a
first generation electrophoresis chamber during which methods were established to
study the effects of gravity on the free flow electrophoresis process. These
studies showed, among other things, that protein and cell samples whose specific
gravities varied significantly from that of the carrier buffer could not be pro-
cessed at flow rates required to separate materials having small differences in
electrophoretic mobility. These data, documented in previous MDC publications,
were used to demonstrate to the drug companies that laboratory test data were
available concerning proteins and cells which illustrate the limit that gravity
does impose on their processing by free flow electrophoresis.
The initial interactions with pharmaceutical companies stimulated several of them .
to participate in the study to various degrees. Two companies in particular
wished to cooperate with us in developing a better understanding of products of
interest to them. A series of follow up meetings with laboratory personnel from
both MDAC-St. Louis and the participating drug companies ensued. The choice of
material to be tested, assays to be used and the frequency of testing were estab-
lished. Protocols were prepared based on previous MDAC-St. Louis company funded
research, the capabilities of the .laboratories, logistics of sample transport, and
company policies concerning management of proprietary data. One of the major
considerations of the protocols was control of the release of information. The
protocols emphasized that the pharmaceutical company would have final say as to
how the data would be represented.
During this contract, however, interlaboratory testing was accomplished with Only
one company. The time involved in developing joint protocols, obtaining product
standards and our familiarization with new assay procedures for the products
suggested by the second participating company did not allow sufficient time in
this contract to obtain electrophoretically separated product data for this report.
A data base concerning AHF VIII and other blood components was developed upon
which MDAC-St. Louis established a technology interchange with the participating
pharmaceutical companies. As a result of this exchange, a preliminary characteri-
zation of AHF VIII and other important blood components by free flow electrophore-
9
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sis was accomplished. This, in turn, we believe, has enhanced the level of
interest of those companies in the potential offered by processing Pharmaceuticals
in space. Initial interlaboratory tests with the pharmaceutical company were
conducted with cryoprecipitate as a starting material. Protein assays and clotting
times on the electrophoretically separated cryoprecipitate were initially conducted
at MDAC-St. Louis. Early tests in which the separated samples were sent to parti-
cipating companies for antigen assays showed deterioration due to problems associ-
ated with logistics. The cooperating company recommended and assisted MDAC-
St. Louis in establishing an MDAC-St. Louis capability to carry out the required
antigen assays eliminating delays and other factors tending to compromise test
results. During these early cooperative tests we determined that the many varia-
bilities of cryoprecipitate made it unsuitable as a research tool for free flow
electrophoresis. It remains, however, a viable candidate for space bioprocessing
since these variabilities would be insignificant in large scale processing.
As a consequence, the more uniform, commercially available antihemophilic factor
RVIII, Hemophil , was chosen for laboratory testing. Samples were prepared by
P
dissolving 0.7 mg of Hemophil in 0.0025M diethylbarbituric acid/sodium diethyl-
barbiturate, pH = 8.3. The same buffer was used as the carrier fluid for the elec-
p
trophoretic separation. A typical separation of Hemophil is shown in Figure 1.
Samples collected during sample streaming with no voltage applied to the chamber
showed that all protein materials were exiting through tubes 19 and 20 of 96
outlet tubes. When an electrical field strength of 48 volts/cm was applied across
the width of the chamber and allowed to stabilize for 30 minutes, samples were
collected in tubes 20 through 56. Each tube was analyzed for total protein, AHF
VIII clotting activity and AHF VIII antigen activity.
The results of these runs showed that AHF VIII migrated in the electric field and
that the antigen moiety and the bulk of the clotting moiety moved with the fastest
moving protein peak. AHF VIII can be separated from a portion of the unwanted
proteins found even in the most highly purified commercial preparations. This is
of interest to the pharmaceutical companies because additives (required in their
purification procedure, snd which may cause toxic side effects) are not. needed
'• r. \r.i-. <• !«•/.*. r ',-.>*i(.,rt;:-. 'i •. ;.r','.'-.::, All'rwir. nio1eo.il *r Oi VjOCiaOori <>1 AHf VH1
occurs, the clotting properties are still intact. Since the patient with classic
hemophilia lacks only the clotting moiety, its dissociation is not a deterrent to
10
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further investigation of this product. Both participating pharmaceutical companies
expressed interest in a purified clotting moiety as a possible product. A small
amount of highly purified, slow moving material showing clotting activity was
R
noted in typical AHF VIII separations of Hemophil . This fraction is of particular
interest to one of the companies since it provided a unique form of clotting
materials which could be used to study AHF VIII by new immunological techniques.
One sample sent to the participating laboratory was concentrated at MDAC-St. L-ouis
by lyophilization. The resultant rehydrated sample contained no antigenic activ-
ity, indicating the possible removal, during processing, of a cryoprotective
material. We are now investigating this loss of activity in-house by recombining
several separated fractions. This finding highlighted the logistical problems to
be encountered in transporting materials from one laboratory to another for con-
ducting specialized tests. It emphasizes the need for MDAC-St. Louis to establish
a broad base biological capability for complete in-house product evaluation of
separated materials.
11
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As an adjunct to the contractual studies, (OAC-St. Louis conducted company funded
research on the electrophoretic separation of normal human plasma. A typical
separation is shown in Figure1 2. It may be possible to obtain all of the important
blood fractions of medical importance in purified form in a single continuous
process. Gamma globulins, used to protect against bacterial and viral diseases,
are slow moving materials whereas albumin, used as a plasma expander, is very fast
moving. These materials are currently obtained commercially by precipitation
methods, but in such methods many important components, such as AHF VIII, other
clotting factors, alpha antitrypsin, etc., may be neglected, lost or denatured by
the process. We are currently developing assays to qualitatively and quantita-
tively identify these individual components and their position in the separation
field. Figure 3 presents an example of purified fibrinogen mobility in the
MDAC-St. Louis instrument. Under the same chamber operating conditions, the
fibrinogen peak is apparently present in the same collecting tubes (37 through 40)
in both the normal plasma sample and the purified fibrinogen sample.
A process in which all blood components can be obtained in a single step is of
significant interest to both participating companies from the standpoint of
economics as well as expansion of their product line.
100
0.8 mg/ml
440 Volts
60 mAmps
Mobility
10 40
Sample Tube Number
Figure 2. Human Plasma Electrophoresis
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4.0 PRODUCT EVALUATION
There is almost an unlimited number of candidate biological products from humans,
animals and plants, that potentially can be improved by space processing. It is
only necessary, however, to show that one or more materials can be beneficially
produced in space. Thus, a selective evaluation of candidate products is very
desirable so that sufficient in-depth analysis can be performed on promising
candidates. .
From a list of candidate products identified in previous studies or suggested in
discussions with the pharmaceutical industry and the medical and academic communi-
ties, twelve products were selected for in-depth evaluation. Technical, medical
and economic data were collected for each product. A synopsis of these data is
shown in Figure 4. These data permitted a selection of six of these products to
serve as "models" for an additional market analysis to determine the commercial
viability of their being processed in space. The six products were chosen on the
basis of a "humanitarian value index" which took into account the number of
patients, severity of the disease to be treated, potential space improvement to
the manufacturing process, competitive products and the production facility
requirements. Using this index as a guide, the six products selected were alpha-
antitrypsin (A-AT), antihemophilic factor (AHF), beta cells, erythropoietin (ESF),
epidermal growth factor (EGF), and interferon.
Alpha-antitrypsin is a protein found in human blood that inhibits the destructive
action of the enzyme trypsin. It is believed that the uncontrolled presence of
trypsin in the lungs results in tissue damage producing emphysema. According to
our estimates, approximately 100,000 people in the United States severely afflicted
with this disease demonstrate abnormally low levels of A-AT in their blood. The
commercial scale isolation and purification of A-AT through space processing may
provide the first pharmacological approach to containing the damage of emphysema
due to this enzyme deficiency.
Antihemophilic Factor VIII (AHF) is one of the 13 clotting factors present in the
blood- Since each factor works in sequence for clot formation, lack of any one
factor will result in bleeding. An AHF VIII deficiency, hemophilia A, is about 5-10
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times more prevalent than the reduction or absence of any other clotting factor.
This deficiency affects more than 20,000 Americans, mostly males, and can be kept
under control by replacement therapy. It is of interest primarily because some of
the hemophiliacs develop antibodies to current preparations and because hepatitis
virus is a hazardous contaminant that is not always detected. Higher purification
may eliminate these problems. It is also of significant interest in that up to 9
million of the 12-13 million pints of blood collected annually in this country may
be used to produce AHF VIII for these approximately 20,000 patients. Newer
methods, such as continuous flow electrophoresis, could recover other products,
now lost, to meet other medical needs.
Beta cells in the pancreatic islets of Langerhans produce a hormone known as
insulin. The physiological function of this hormone is to aid in the regulation
of carbohydrate metabolism. A deficiency in production of this hormone results in
diabetes me!litus, often called "juvenile onset" or "insulin dependent" diabetes.
The present United States population of known insulin dependent diabetics is
believed to be 1.5-3 million people concomitant with an additional 3.5-7.0 million
adult onset diabetics who may eventually require insulin as their disease pro-
gresses. While daily injections of insulin can sustain the patient's life, it
does not eliminate all the other pathology associated with diabetes. It is
anticipated that a single injectable transplant of human beta cells may provide a
surrogate pancreas and thus eliminate the need for further insulin injections.
Epidermal growth factor is a protein produced in the submaxillary glands. It has
the fundamental property of stimulating the production of ectodermal (skin origin)
tissue. In clinical situations where the skin is damaged by burns and wounds of
various types, application of EGF to the damaged areas could result in their rapid
restoration to normal function. This substance also has a trememdous potential
for both supplementing and partially replacing fetal animal serums in tissue
culture systems. .
Erythropoietin stimulates red blood cell production in the bone marrow. This
protein hormone is a product of specific kidney cells, and chronic renal failure
can result in an anemic condition. Patients on kidney dialysis are especially in
need of this hormone since their kidney may no longer produce ESF and only blood
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transfusions can replace the red blood cells lost after their normal 120 day life
cycle.
Interferon is a protein substance produced by blood lymphocytes and fibroblasts
challenged by a virus. This interferon offers temporary immunity to other body
cells against most challenge viruses when subsequently attacked. Preliminary human
clinical trials indicate this natural body product has great therapeutic potential
against many diseases of viral or suspected, but not proven, viral origin such as
cancer. It is probably one of the most sought after candidate products today with
about one hundred pharmaceutical companies and universities actively conducting
research and development related to its potential therapeutic commercialization.
Each of these products allows evaluation of a processing system in a different
mode. AHF and A-AT are contained in a protein mixture from blood plasma and would
utilize a protein electrophoresis system for separation; both ESF, the product of
a kidney cell culture, and EGF, the product of submaxillary gland culture, would
utilize the cell electrophoresis, tissue culture and protein electrophoresis
systems; beta cells would either be the product of the electrophoretic separation
of numerous minced human pancreata or the product of a pancreas cell tissue culture
and its subsequent cell electrophoresis. Interferon is contained in a lymphocyte
tissue culture medium which would use the protein electrophoresis system .for
separation. Definition of a processing system to produce these products would
provide a true multiproduct system evaluation.
These six products were further evaluated to determine total market potential,
market risk, and the target market for each. These results are summarized in
Figure 5. AHF was determined to have a market for about 500 x 10 units per
year. It was estimated that at best, 30% of this market could be captured by the
space processed material. Purity requirements for those hemophiliacs suffering
antigenic reaction to current preparations, and probable reduction of hepatitis
were major considerations. These were partially offset by the expected higher
cost of space processing. The ESF market was somewhat more difficult to determine
since the product is not currently available commercially; however, it was esti-
q
mated that 7.0 x 10 units annually would be necessary to treat the anemia
secondary to diseased kidneys. An arbitrary value of 30% of the market was
targeted for space processing. Beta cells have the potential of curing diabetes
17
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mellitus and thus would primarily be a single, total market rather that an annual
requirement. It was projected that five years might be necessary to eradicate
this disease. Subsequent requirements would only be for those newly contracting
this disease. This market was projected to be 630,000 doses/year for five years
followed by an annual need for 150,000 doses to cure new onsets.
The epidermal growth factor market is very difficult to estimate because the
dosage and treatment regimen has not been established. It was estimated that 2.6
kg of EGF would be required annually to treat only 30% of the anticipated annual
market of 14,000 burn patients. On the other hand 26,400 kg of A-AT would be
required annually to meet the needs of 100,000 emphysema patients. Only 30% of
this market is expected to be achieved by space processing, however, because of
both the possible competition from ground processing after the market is developed
and the reluctance of physicians to give long term prophylactic treatment to
patients with no immediate overt difficulties. There is a current annual require-
ment for 6.6 x 10 units of interferon. Because current ground production is 3
x 10 units with heavy competition to develop new production techniques, we
have estimated that space production would achieve only 10% of the market.
Of the six products subjected to detailed market analyses, three were chosen to -
serve as model products. These products were antihemophilic factor VIII, beta
cells, and erythropoietin. All six products were used for the development of re-
quirements for a multiproduct processing system; the three model products were
used to exercise the conceptual system and assess developmental feasibility.
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5.0 PROCESS SYSTEM REQUIREMENTS
The purpose of this task was to assess the requirements for a multiproduct produc-
tion facility to produce three "model" pharmaceutical products selected from those
studied in the task regarding product requirements and analysis. Such a facility
must be in conformance with good manufacturing practices imposed by the Food and
Drug Administration either as written or with appropriate modifications for space
processing. Therefore, with the aid of a participating pharmaceutical company,
contact was made with the FDA to start exploratory discussions of the space biopro-
cessing concept, the candidate substances considered for production and the appli-
cable governing regulations. This agency was very cooperative and appreciative of
being brought into our program at the conceptual stages. Agency guidance will be
continued through meetings with representatives from the divisions they consider
pertinent to this concept. These governing regulations were previously reviewed
by us and the results are. summarized in Figure 6. Modifications were recommended
in several areas. Where the operators and supervisors were required to have suf-
ficient experience and training, qualifying statements were added to permit space-
craft crew operations and ground supervision. The requirements on facilities and
equipment require modification to allow onboard irreversible (nonretrievable)
storage of waste, recycling of some materials, and the potential for remote opera-
tion and monitoring of automatic processing systems. These FDA representatives
could see no insurmountable problems with regard to space bioprocessing as outlined
by us.
Our approach to establishing process requirements was to evaluate current ground
processes for three products to determine required process functions. Erythro-
poietin is now produced commercially in limited amounts from plasma of anemic'
sheep, while researchers use the urine of aplastic anemic humans as a source. The
erythropoietin in either case is separated by precipitation techniques. Beta
cells are obtained from minced human pancreatic tissue using an enzymatic diges-
tion process followed by density gradient separation. .Antihemophilic factor is
separated from human plasma by protein precipitation. Therefore, the minimum
requirement for space production of these Pharmaceuticals from natural materials
is the ability to separate cells and proteins from unwanted constituents in a
mixture. In addition, production of desired cells or protein products can probably
be enhanced by cell culture of selected strains.
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21 1 .42
SUBJECT
GENERAL
PROVISIONS
FACILITIES
EQUIPMENT
PRODUCTION
AND CONTROL
PROCEDURES
COMPONENTS
(CONSTITUENTS)
MODIFICATION
ALLOW REMOTE MONITOR-
ING BY RESPONSIBLE
PERSONNEL
ALLOW VARYING LOCATION;
IRREVERSIBLE ON BOARD
WASTE STORAGE
ALLOW FLUID RECLAMA-
TION
ALLOW AUTOMATIC CON-
TROL WITH REMOTE
MONITORING
REMOVE VISUAL EXAMINA-
TION, ALLOW RECLAMATION
OF COMPONENTS FOR
MULTIPLE PRODUCTS
Figure 6. .Good Manufacturing Practices Modifications
(Part 211, Title 12 Chapter 1, 1977)
Our method of choice for cell and protein separation is continuous free flow
electrophoresis. Large scale commercial application of this technique for ground
processing is restricted due to the effects of gravity in limiting throughput and
resolution. It is anticipated that minimizing thermal convection and sample
velocity variations by operating in microgravity will significantly aid electropho-
resis. The improvement in the throughput was estimated to be about two orders of
magnitude for both cells and proteins.
Improved separation of cells may allow the culturing of selected strains to greatly
increase pharmaceutical production. Separation of high yield cells from human
kidney tissue and subsequent culture would be superior to either sheep plasma or
human urine as a source for erythropoietin. This protein hormone would then be
separated from the culture media by electrophoresis. For beta cell production,
the tradeoff between electrophoresis of human pancreatic tissue alone, or its
electrophoresis and subsequent cell culture, is in favor of electrophoresis and
culture at relatively low throughput. Assuming significant culture of beta cells
can be developed, electrophoresis would then be used to separate beta cells for a
high yield, almost pure culture.
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Evaluating the process for space production of the three selected "model" products
requires the evolution of mass flow rates and capacities for the equipment required
for the process.. A schematic of a typical mass flow balance for the space produc-
tion of pancreatic beta cells is shown in Figure 7. The use of the mass balance
concept forces a delineation of what must be accomplished in the process for each
product in a stepwise fasnibh. the depicted quantities of materials at each step
will quickly determine if the process is feasible with current technology, where
areas of information must be obtained to fill in the gaps, and the anticipated
recurring transportation costs to haul the material to and from space. While it
does not define the total cost of the system, it does give the prospective manufac-
turer and NASA a general idea of the size, power and weight of the processing
equipment as well as the extent and type of utilities and storage requirements.
The length of the missions will be defined to determine economic feasibility.
This has to be interwoven with the NASA program and schedules to determine if, and
when, a vehicle capability will be available to support such a manufacturing
facility.
 ; . ,
6.B»}09 CELLS
68 ml BUFFER
SUPPLIES
NUTRIENT
OXYGEN
co2
NaOH
H2O
TOTAL
11.6 Kg
2.5
2.7
0.27
31.1
48.1 Kg
TANKAGE
48.1 Kg
TOTAL
97.2 Kg
Figure 7. Space Production - Beta Cells
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These mass balances were defined for three cases with each product: space produc-
tion, ground production, and one alternative combination of space and ground
production. These possibilities were compared using space transportation cost as
opposed to quantities of electrophoresis chambers required for ground processing
modes. The results of this comparison are shown in Figure 8. With antihemophilic
factor separation from cryoprecipitate, the advantages of space separation are
obvious. For a transportation cost differential of $3.4M the complexity and cost
of 3878 chambers required for separation on the ground is reduced to that of 20
chambers in space. This cost is also a relatively small fraction of the $25.8M
value of the separated products. For beta cells, the product value is much higher
at $10CW, based on equivalent insulin injections, however, the amount of product
and the scale of the process is smaller. Again, there is a large reduction in the
number of electrophoresis chambers required favoring space processing. For
erythropoietin production, the small amount of hormone product in the culture
media required both large scale cell culture and electrophoresis. The large scale
favors ground culture; however, the large number of chambers (23,042) required for
ground separation favors a space separation/ground culture .combination. Erythro-
poietin process requirements make it much less desirable as a product for the
multiproduct production system than either beta cells or antihemophilic factor.
PRODUCT
AHF/CRYOPRECIPITATE
($25M VALUE)
GROUND
SPACE
BETA CELLS
($100M VALUE)
GROUND
SPACE
GROUND/SPACE
ERYTHROPOIETIN
GROUND
SPACE
GROUND/SPACE
CULTURE
SIZE
N/A
N/A
0.8L.
2.0L
5,0 L
375L
375L
433L
ELECTROPHORESIS
CHAMBERS
3878
20
27
1
31
23042
115
1089
TRANSPORTATION
(SUPPLIESONLY)
$3.4M
S0.05M
$0.03M
$18. 7M
$ 8.2M
Figure 8. Space Production Benefit Comparison
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Consequently, erythropoietin was included in the subsequent requirements analysis
for a multiproduct space processing system only to provide a capability for
applied research on the material'
Based, on the mass balance analyses done on the three products, a multiproduct pro-
duction system shown .in Figure 9 would be capable of satisfying 30% of the poten-
tial market for antihemophilic factor VIII and 20% of the potential beta cell
market per year. In addition, it could be used for trial runs of erythropoietin
production to see if it would be improved as a space processed product candidate.
The two liter culture vessel and supporting system would be used for culturing beta
cells or erythropoietin producing cells, separated by electrophoresis from human
pancreatic or kidney cells, respectively. After culture, the beta cells would be
separated from lysed and unwanted cells, rate frozen, and stored in a freezer.
Erythropoietin would be separated from concentrated culture media, analyzed,
lyophilized, and stored. .For. antihemophilic factor production, reconstituted
cryoprecipitate would undergo electrophoresis, analysis, lyophilization, and
storage.
CULTURE SUBSYSTEM SEPARATION SUBSYSTEM
3000kg
CYROPRECIPITATE
SUPPLIES
H2O
31 kg
NUT
RIENT
12 kg
°2
3kg
CO2
3 kg
NaOH
<1 kg
36ml/hr
MEMBRANE
CONCENTRATOR
ANALYSIS AND PRESERVATION SUBSYSTEM
Figure 9. Multi-Product Process System
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At a subsequent time in the study, three additional products were "processed"
through the system to see if any modifications to the concept were required.
Except for minor changes in chemical constituents and instrument settings to
create a more compatible environment for each candidate product, the hardware is
designed and sized as a truly multiproduct production system. The mass balance
concept should be applied to other classes of products in future studies to
determine if they also are compatible with the size of the system.
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6.0 LESSONS LEARNED
During this study a number of lessons have been learned about obtaining and fos-
tering commercial producer participation in studies of space processing* These
should be given due consideration in formulating plans for future studies of this
nature. They are presented here in brief, and MDAC-St. Louis recommends that they
be adopted as elements in the NASA model for exploring other market sectors con-
sidered for the commercialization of space.
The key to involving industry in space processing is to establish a ful ly business-
like footing for their participation. In most cases, the producer industry is
relatively unfamiliar with the space environment, operations in space and the
requirements and techniques of designing and integrating systems hardware to be
flown in space missions. Dealing directly with NASA would involve them in a new
form of governmental interface to which they are not accustomed.
By establishing a buffer team between itself and the industry with which it
desires to build participatory agreements, NASA can establish the businessman-to-
businessman relationship so essential to nurturing commercial enterprise in space.
The aerospace company chosen for the buffer team should have established a compe-
tence in dealing with the particular process NASA wishes to advance as a candidate
for production operations in space. Moreoever, the company should have made a
significant commitment on its own, in terms of funds and manpower, to the develop-
ment of that process before NASA chooses that firm to serve on the buffer team.
The buffer team should also include an independent business analysis firm special-
izing in the particular industry to be approached. The right business analysis
firm not only knows the industries of interest, but is. familiar with the particular
environment in which the producers operate. It has access to business documenta-
tion resources beyond the aerospace horizon; and, most importantly, such a firm
will know key management and technical personnel of these companies plus the
correct business basis on which to approach them.
The candidate producer firms identified by the buffer team should be subjected to
a penetrating business analysis by the business consultant member of the team.
This analysis should include such factors as: the firm's annual sales and growth;
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the size of the company; the new products it has marketed; the tenure of the
firm's senior officers; the surplus funds available for investment; the size of
the firm's R&D budget; and the identifiable constraints on the firm's growth. In
addition, there will be factors requiring evaluation which are peculiar to the
specific class of industry being approached.
Having made contact with the companies by introductory letter, follow-up telephone
calls should arrange for a formal presentation at the producer's own facility.
After establishing a degree of rapport with their business or technical management,
the presenting company should tailor each presentation to the interests of the key
people in each producer company, i.e., the corporate decision makers and senior
technical personnel.
Personnel making the presentation should be thoroughly familiarized with the seg-
ment of industry they will be visiting; at least one member should have credible
experience in that producer industry. All members should be prepared to speak the
vocabulary distinct to that industrial field of endeavor. The presenters should
be a systems team that is capable of addressing all aspects of space processing to
the audience's satisfaction. Not only must they be knowledgeable in the area of
products and processes, but also familiar with space flight systems and how day-
to-day activities in space are carried out. They must be thoroughly prepared, as
well, to discuss resource requirements, costs and manpower, and schedules. Inclu-
sion of a life sciences specialist in the team is highly desirable so that ques-
tions on man's contributions and requirements in space can be answered.
The presentation approach should reflect the businessman-to-businessman relation-
ship desired between the buffer team and the manufacturing firm. It must refTect
that industry is profit oriented rather than knowledge oriented; research must
ultimately lead to increased corporate profit. By selecting products of particular
interest to that company and presenting relevant market and business forecasts, a
profit potential can be demonstrated in a way to engage both the technical and
rn's.-*-<fyt!ia*'--'-ft. s.nt !•??.•*; tiers: <rf' *.£« #w!'igtie&* liJ i^fcg * <^sterv#i1.'** #pw«j»£k rrt 6M1 pTestftt-
tation, especially with technical and business values familiar to the audience,
will give individuals an excellent chance to contribute to the discussions and to
realize that their experience and participation would greatly enhance the program.
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In this situation, the presentation approach should reflect that a joint working
arrangement between the visited company and the aerospace industry would be
mutually beneficial, using the strengths of each partner to achieve new goals. It
must convey the attitude: "We are deeply involved and would like you to join us"
" . ' • ' * • "
rather than "You tell us what we can do for you in space." If the presentation
features working hardware, mathematical analyses and models, as well as preliminary
product data with their related market and risk analyses, the audience will feel
that the presenters have a strong corporate investment in the concept, both
financially and in terms of manhours of effort.
' •• • ' i •
During the presentation, the question is invariably asked of the presenter, "Why
should we manufacturers be interested in space processing?" Placing a good reason
for their interest early in the presentation can forestall the inquiry. The
reason can easily be developed by identifying the visited company with a candidate
product that has the potential of being produced in space and that also complements
their already existing product line. We have found it is also essential to indi-
cate very early in our presentations that the products discussed are of the very
low volume-very high value type. Many of the proprietary pharmaceutical companies
think in terms of large volume-low cost products which are not applicable in the
space operations we visualize.
Results of the presentations will develop relatively slowly. The companies
visited will take time to digest what is presented and investigate the claims
made. Experience in this study has shown that this phase will take about three
months. If results of the initial investigation are favorable, the company will
present the concept to their corporate management. This second phase usually will
take two more months. The. formal development of participating documentation •
(e.g., protocols, agreements, etc.) and approval of budgets will ordinarily con-
sume an additional six to twelve months. All during this time, routine contact
between the two companies should be maintained with pertinent management and
technological data exchange by both sides as required.
During this period, it is extremely important not to exploit the manufacturing
company names or the products they have under consideration. If such information
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became generally known without the consent of the candidate participant/coopera-
tion would probably be terminated. The privacy of a manufacturing company consid-
ering participation must be respected until the firm decides to announce publicly,
for itself, its intent to participate in the exploration of space applications.
A data base concerning a potentially profitable candidate product must be developed
upon which a technology interchange can be established between the interfacing
company and the candidate producing company. Cooperative laboratory activities
are essential tools in building the required data base. In this way MDAC-
St. Louis established a technology interchange with the participating pharmaceuti-
cal companies. This, in turn, we believe, has enhanced the level of interest of
these companies in the potential offered by processing Pharmaceuticals in space.
Many potential products can be proposed for space processing by reviewing the
literature and discussing the subject with professionals in the field of interest.
Many of the suggestions may be of interest scientifically for their own sake but
will have little chance of being rapidly adopted by the workers in that field if
they offer no substantial improvement over existing materials. If the companies
do not see a significant return on their investment in research and development of
a product they will ignore that product.
Development of market data on products important to candidate participating firms
is a key to securing their interest. A search of the literature, supplemented by
consultations with clinical authorities will provide the information necessary to
develop a picture of the current market open for the model products. Reasonable
assumptions, based on the guidance of clinical research teams, will yield use
market projections for advanced clinical uses. Finally, appropriate business'risk
analysis should be employed to assess the market risks for processes and products
as they move from initial R&D commitment through ground and flight experimentation
to achieve successful flight production demonstrations. By offering these prelimi-
nary analyses to prospective participators, much useful data can be obtained
during the presentation itself. Most important, the potential participating firms
will be assured that the presenter has a business understanding and an investment
attitude appropriate for cooperative endeavors for their mutual benefit.
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A hardware system that is capable of producing a variety of products with only
minor operational changes, e.g., Instrument settings and chemical substrates,
would offer significant operational, logistics and cost advantages to a producer.
Using conservative assumptions based on data from the literature, tempered by
laboratory experience, the requirements for such a system can be developed and its
significant operating characteristics can be defined. This was the approach used
by MDAC-St. Louis to define a system for processing Pharmaceuticals in space. All
of the twelve biological products reviewed in this study could exercise the
system in part, or in its entirety, thus supporting the concept of a true multi-
product system. . i . ' •
While this study was done to assess the commercial feasibility of manufacturing
pharmaceutical products in space, it serves as a model for those who wish to
consider other processes or prqducts in the same environment. The use of the mass
balance analytical concept forces a delineation of what must be accomplished in
the process for each product in a stepwise fashion. The calculated quantities of
materials at each step will quickly determine if the process is feasible with
current technology, where the areas of information must be obtained to fill in the
gaps, and anticipated recurring transportation costs to haul the material to and
from space. While it does not define the total cost of the system, it does give
the prospective manufacturer and NASA a general idea of the size, power and weight
of the processing equipment as well as the extent and type of storage requirements.
The length of the missions will be defined to determine economic feasibility.
This will have to be interwoven with the NASA program and schedules to determine
if, and when, a vehicle capability will be available to support such a manufactur-
ing facility. Legal and regulatory considerations will also have to be defined.
Recommendations for future work are presented in Figure 10. It is recommended
that drug firm involvement be continued and encouraged;both in ground research and
product evaluation. Because of companies' sensitivity about government interfer-
ence and disclosure of trade secrets, each company should be dealt with on an
individual basis with some pther^pniyate firm serving as a buffer or interface
between the individual cohipfh^ e|^ ^^ ttie government. Heavier involvement through
evolutionary processes wii|y|r6i|lBfty"T;e9d to direct participation in space activi-
ties. Such participation Wiihtogtcally require a user development laboratory for
these companies' product
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• CONTINUE USER INVOLVEMENT
-'GROUND RESEARCH
- PRODUCT EVALUATION
• INDIVIDUAL DEALINGS WITH DRUG COMPANIES
- SENSITIVE ABOUT GOVERNMENT INTERFERENCE
- CONCERNED ABOUT TRADE SECRETS
MOVE TOWARD USER PARTICIPATION IN SPACE
ACTIVITIES
- USER DEVELOPMENT LABORATORY FOR
PRODUCT DEVELOPMENT
EXAMINE EQUIPMENT SIZE AND COST
DEVELOP MASS BALANCES FOR EACH NEW
PRODUCT CONSIDERED
Figure 10. Recommendations
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